Japanese Encephalitis Vaccine | Japanese Encephalitis Virus | CDC
WEBMay 15, 2024 · One Japanese encephalitis vaccine (called IXIARO) is available in the United States. Japanese encephalitis vaccine is approved for use in children aged 2 months and older and adults. The vaccine should be considered for some travelers at higher risk of Japanese encephalitis.
Japanese Encephalitis Vaccine – IXIARO® - Valneva
WEBJul 11, 2019 · IXIARO®, or JESPECT® in Australia and New Zealand, is an inactivated Japanese encephalitis vaccine and is the only Japanese encephalitis vaccine currently approved for use in the United States, Canada and Europe.
Japanese Encephalitis Vaccine Information for Healthcare Providers
WEBMay 15, 2024 · One inactivated Japanese encephalitis (JE) vaccine (manufactured as IXIARO) is available in the United States. JE vaccine is approved for use in children aged 2 months and older and adults. JE is a very low risk disease for most travelers.
IXIARO | FDA - U.S. Food and Drug Administration
WEBIXIARO. STN: BL 125280 Proper Name: Japanese Encephalitis Vaccine, Inactivated, Adsorbed Tradename: IXIARO Manufacturer: Valneva Austria GmbH Indication: For the prevention of disease caused by...
Japanese Encephalitis Vaccine Evidence to Recommendations
WEBSep 9, 2024 · JE-VC (manufactured as IXIARO) is the only JE vaccine licensed and available in the United States. JE-VC is manufactured by Valneva Austria GmbH. In March 2009, the US Food and Drug Administration (FDA) licensed JE-VC for use in adults aged ≥17 years. In June 2009, the Advisory Committee on …
Ixiaro Vaccine: Schedule, Side Effects & Warnings - Drugs.com
WEBJan 3, 2024 · What is Ixiaro vaccine? Ixiaro vaccine is used to help prevent Japanese encephalitis in adults and adolescents who are at least 17 years old. Japanese encephalitis is a serious disease caused by a virus. It is the leading cause of viral encephalitis (inflammation of the brain) in Asia.
Japanese Encephalitis Vaccine: Recommendations of the Advisory ...
WEBJul 7, 2019 · Inactivated Vero cell culture–derived JE vaccine (Ixiaro [JE-VC]) is the only JE vaccine that is licensed and available in the United States. In 2009, the U.S. Food and Drug Administration (FDA) licensed JE-VC for use in persons aged ≥17 years; in 2013, licensure was extended to include children aged ≥2 months.
Japanese Encephalitis Virus Vaccine (Intramuscular Route)
WEBJapanese encephalitis virus vaccine, inactivated, adsorbed (Ixiaro®) is used to prevent infection caused by the Japanese encephalitis virus. It works by causing your body to produce its own protection (antibodies) against the virus.
WEBIXIARO is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus (JEV). IXIARO is approved for use in individuals 2 months of age and older.
Japanese Encephalitis Virus Vaccine (Ixiaro) - Cleveland Clinic
WEBJapanese Encephalitis Virus Vaccine (Ixiaro) The Japanese encephalitis vaccine prevents Japanese encephalitis infections. This infection causes fever, headaches and neck pain. It can also affect cognitive functioning, leading to confusion and behavior changes.